Нативное Т1- и Т2-картирование времен релаксации миокарда при магнитно-резонансной томографии сердца: области применения

Автор: Мершина Е.А., Рыжкова Е.В., Лисицкая М.В., Харлап М.С., Синицын В.Е.

Журнал: Сибирский журнал клинической и экспериментальной медицины @cardiotomsk

Статья в выпуске: 3 т.38, 2023 года.

Бесплатный доступ

Магнитно-резонансная томография (МРТ) сердца широко применяется в диагностике сердечно-сосудистых заболеваний, так как позволяет неинвазивно оценить характер поражения тканей сердца. В последние годы в рутинную практику активно внедряются методы нативного картирования Т1- и Т2-времен релаксации миокарда. Нативное Т1-и Т2-картирование дает возможность количественного анализа состояния миокарда. Данная методика может быть использована для выявления и оценки широкого спектра поражений миокарда на различных этапах патологического процесса без необходимости контрастирования гадолиний-содержащими препаратами. В настоящем обзоре мы рассмотрим применение нативного Т1- и Т2-картрирования миокарда при различных заболеваниях сердца.

Еще

Магнитно-резонансная томография сердца, картирование миокарда, заболевания сердца, ишемическая болезнь сердца, кардиомиопатия, амилоидоз, болезни накопления, миокардит

Короткий адрес: https://sciup.org/149143648

IDR: 149143648 | DOI: 10.29001/2073-8552-2023-39-3-49-57

Список литературы Нативное Т1- и Т2-картирование времен релаксации миокарда при магнитно-резонансной томографии сердца: области применения

Kim P.K., Hong Y.J., Im D.J., Suh Y.J., Park C.H., Kim J.Y. et al. Myocardial T1 and T2 mapping: techniques and clinical applications. Korean J. Radiol. 2017;18(1):113–131. DOI: 10.3348/kjr.2017.18.1.113.
Piechnik S.K., Ferreira V.M., Lewandowski A.J., Ntusi N.A., Banerjee R., Holloway C. et al. Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLLI. J. Cardiovasc. Magn. Reson. 2013;15(1):13. DOI: 10.1186/1532-429X-15-13.
Mewton N., Liu C.Y., Croisille P., Bluemke D., Lima J.A. Assessment of myocardial fi brosis with cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 2011;57:891–903. DOI: 10.1016/j.jacc.2010.11.013.
Radunski U.K., Lund G.K., Stehning C., Schnackenburg B., Bohnen S., Adam G. et al. CMR in patients with severe myocarditis: diagnostic value of quantitative tissue markers including extracellular volume imaging. JACC Cardiovasc. Imaging. 2014;7(7):667–675. DOI: 10.1016/j.jcmg.2014.02.005.
Piechnik S.K., Ferreira V.M., Dall’Armellina E., Cochlin L.E., Greiser A., Neubauer S. et al. Shortened Modifi ed Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1- mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J. Cardiovasc. Magn. Reson. 2010;12(1):69. DOI: 10.1186/1532-429X-12-69.
Chow K., Flewitt J.A., Green J.D., Pagano J.J., Friedrich M.G., Thompson R.B. Saturation recovery single-shot acquisition (SASHA) for myocardial T(1) mapping. Magn. Reson. Med. 2014;71(6):2082–2095. DOI: 10.1002/mrm.24878.
Messroghli D.R., Greiser A., Frö hlich M., Dietz R., Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified Look-Locker inversion-recovery (MOLLI) T1 mapping of the heart. J. Magn. Reson. Imaging. 2007;26(4):1081–1086. DOI: 10.1002/jmri.21119.
Messroghli D.R., Radjenovic A., Kozerke S., Higgins D.M., Sivananthan M.U., Ridgway J.P. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn. Reson. Med. 2004;52(1):141–146. DOI: 10.1002/mrm.20110.
Weingärtner S., Akçakaya M., Basha T., Kissinger K.V., Goddu B., Berg S. et al. Combined saturation / inversion recovery sequences for improved evaluation of scar and diffuse fibrosis in patients with arrhythmia or heart rate variability. Magn. Reson. Med. 2014;71(3):1024–1034. DOI: 10.1002/mrm.24761.
O’Brien A.T., Gil K.E., Varghese J., Simonetti O.P., Zareba K.M. T2 mapping in myocardial disease: a comprehensive review. J. Cardiovasc. Magn. Reson. 2022;24(1):33. DOI: 10.1186/s12968-022-00866-0.
Willerson J.T., Scales F., Mukherjee A., Platt M., Templeton G.H., Fink G.S. et al. Abnormal myocardial fluid retention as an early manifestation of ischemic injury. Am. J. Pathol. 1977;87(1):159–188.
Wisenberg G., Prato F.S., Carroll S.E., Turner K.L., Marshall T. Serial nuclear magnetic resonance imaging of acute myocardial infarction with and without reperfusion. Am. Heart J. 1988;115(3):510–518. DOI: 10.1016/0002-8703(88)90798-3.
Ugander M., Bagi P.S., Oki A.J., Chen B., Hsu L.Y., Aletras A., et al. Myocardial edema as detected by pre-contrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. JACC Cardiovasc. Imaging. 2012;5(6):596–603. DOI: 10.1016/j.jcmg.2012.01.016.
Goldfarb J.W., Arnold S., Han J. Recent myocardial infarction: assessment with unenhanced T1-weighted MR imaging. Radiology. 2007;245(1):245–250. DOI: 10.1148/radiol.2451061590.
Bulluck H., White S.K., Rosmini S., Bhuva A., Treibel T.A., Fontana M. et al. T1 mapping and T2 mapping at 3T for quantifying the area-atrisk in reperfused STEMI patients. J. Cardiovasc. Magn. Reson. 2015;12;17(1):73. DOI: 10.1186/s12968-015-0173-6.
Zia M.I., Ghugre N.R., Connelly K.A., Strauss B.H., Sparkes J.D., Dick A.J. et al. Characterizing myocardial edema and hemorrhage using quantitative T2 and T2* mapping at multiple time intervals post ST-segment elevation myocardial infarction. Circ. Cardiovasc. Imaging. 2012;5(5):566–572. DOI: 10.1161/CIRCIMAGING.112.973222.
Suranyi P., Elgavish G.A., Schoepf U.J., Ruzsics B., Kiss P., van Assen M. et al. Myocardial tissue characterization by combining late gadolinium enhancement imaging and percent edema mapping: a novel T2 mapbased MRI method in canine myocardial infarction. Eur. Radiol. Exp. 2018;2(1):6. DOI: 10.1186/s41747-018-0037-6.
Tahir E., Sinn M., Bohnen S., Avanesov M., Säring D., Stehning C. et al. Acute versus chronic myocardial infarction: diagnostic accuracy of quantitative native T1 and T2 mapping versus assessment of edema on standard T2-weighted cardiovascular MR images for differentiation. Radiology. 2017;285(1):83–91. DOI: 10.1148/radiol.2017162338.
Carrick D., Haig C., Ahmed N., McEntegart M., Petrie M.C., Eteiba H. et al. Myocardial hemorrhage after acute reperfused ST-segment-elevation myocardial infarction: relation to microvascular obstruction and prognostic significance. Circ. Cardiovasc. Imaging. 2016;9(1):e004148. DOI: 10.1161/CIRCIMAGING.115.004148.
Liu A., Wijesurendra R.S., Francis J.M., Robson M.D., Neubauer S., Piechnik S.K., Ferreira V.M. Adenosine stress and rest T1 mapping can differentiate between ischemic, infarcted, remote, and normal myocardium without the need for gadolinium contrast fgents. JACC Cardiovasc. Imaging. 2016;9(1):27–36. DOI: 10.1016/j.jcmg.2015.08.018.
Burrage M.K., Shanmuganathan M., Zhang, Q., Hann E., Popescu I.A., Soundarajan R. et al. Cardiac stress T1-mapping response and extracellular volume stability of MOLLI-based T1-mapping methods. Sci. Rep. 2021;11(1):13568. DOI: 10.1038/s41598-021-92923-4.
Mewton N., Liu C.Y., Croisille P., Bluemke D., Lima J.A. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 2011;57(8):891–903. DOI: 10.1016/j.jacc.2010.11.013.
Mordi I., Carrick D., Bezerra H., Tzemos N. T1 and T2 mapping for early diagnosis of dilated non-ischaemic cardiomyopathy in middle-aged patients and differentiation from normal physiological adaptation. Eur. Heart J. Cardiovasc. Imaging. 2016;17(7):797–803. DOI: 10.1093/ehjci/jev216.
Nishii T., Kono A.K., Shigeru M., Takamine S., Fujiwara S., Kyotani K. et al. Cardiovascular magnetic resonance T2 mapping can detect myocardial edema in idiopathic dilated cardiomyopathy. Int. J. Cardiovasc. Imaging. 2014;30 Suppl. 1:65–72. DOI: 10.1007/s10554-014-0414-z.
Jeserich M., Föll D., Olschewski M. Kimmel S., Friedrich M.G., Bode C. et al. Evidence of myocardial edema in patients with nonischemic dilated cardiomyopathy. Clin. Cardiol. 2012;35(6):371–376. DOI: 10.1002/clc.21979.
Spieker M., Katsianos E., Gastl M., Behm P., Horn P., Jacoby C. et al. T2 mapping cardiovascular magnetic resonance identifies the presence of myocardial inflammation in patients with dilated cardiomyopathy as compared to endomyocardial biopsy. Eur. Heart J. Cardiovasc. Imaging. 2018;19(5):574–582. DOI: 10.1093/ehjci/jex230.
Xu Y., Li W., Wan K., Liang Y., Jiang X., Wang J. et al. Myocardial tissue reverse remodeling after guideline-directed medical therapy in idiopathic dilated cardiomyopathy. Circ. Heart Fail. 2021;14(1):e007944. DOI: 10.1161/CIRCHEARTFAILURE.120.007944.
Caforio A.L., Pankuweit S., Arbustini E., Basso C., Gimeno-Blanes J., Felix S.B. et al.; European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 2013;34(33):2636–2648, 2648a–2648d. DOI: 10.1093/eurheartj/eht210.
Spieker M., Haberkorn S., Gastl M., Behm P., Katsianos S., Horn P. et al. Abnormal T2 mapping cardiovascular magnetic resonance correlates with adverse clinical outcome in patients with suspected acute myocarditis. J. Cardiovasc. Magn. Reson. 2017;19(1):38. DOI: 10.1186/s12968-017-0350-x.
Lurz P., Luecke C., Eitel I., Föhrenbach F., Frank C., Grothoff M. et al. Comprehensive cardiac magnetic resonance imaging in patients with suspected myocarditis: the myoracer-trial. J. Am. Coll. Cardiol. 2016;67(15):1800–1811. DOI: 10.1016/j.jacc.2016.02.013.
Tschöpe C., Ammirati E., Bozkurt B., Caforio A.L.P., Cooper L.T., Felix S.B. et al. Myocarditis and inflammatory cardiomyopathy: current evidence and future directions. Nat. Rev. Cardiol. 2021;18(3):169–193. DOI: 10.1038/s41569-020-00435-x.
Bönner F., Spieker M., Haberkorn S., Jacoby C., Flögel U., Schnackenburg B. et al. Myocardial T2 mapping increases noninvasive diagnostic accuracy for biopsy-proven myocarditis. JACC Cardiovasc. Imaging. 2016;9(12):1467–1469. DOI: 10.1016/j.jcmg.2015.11.014.
Hinojar R., Foote L., Arroyo Ucar E., Jackson T., Jabbour A., Yu C.Y. et al. Native T1 in discrimination of acute and convalescent stages in patients with clinical diagnosis of myocarditis: a proposed diagnostic algorithm using CMR. JACC Cardiovasc. Imaging. 2015;8(1):37–46. DOI: 10.1016/j.jcmg.2014.07.016.
Ferreira V.M., Piechnik S.K., Dall’Armellina E., Karamitsos T.D., Francis J.M., Ntusi N. et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc. Imaging. 2013;6(10):1048–1058. DOI: 10.1016/j.jcmg.2013.03.008.
Ferreira V.M., Piechnik S.K., Dall’Armellina E., Karamitsos T.D., Francis J.M., Ntusi N. et al. Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents. J. Cardiovasc. Magn. Reson. 2014;16(1):36. DOI: 10.1186/1532-429X-16-36.
Spieker M., Haberkorn S., Gastl M., Behm P., Katsianos S., Horn P. et al. Abnormal T2 mapping cardiovascular magnetic resonance correlates with adverse clinical outcome in patients with suspected acute myocarditis. J. Cardiovasc. Magn. Reson. 2017;19(1):38. DOI: 10.1186/s12968-017-0350-x.
Bohnen S., Radunski U.K., Lund G.K., Kandolf R., Stehning C., Schnackenburg B. et al. Performance of t1 and t2 mapping cardiovascular magnetic resonance to detect active myocarditis in patients with recent- onset heart failure. Circ. Cardiovasc. Imaging. 2015;8(6):e003073. DOI: 10.1161/CIRCIMAGING.114.003073.
Мершина Е.А., Синицын В.Е., Ларина О.М. Магнитно-резонансная томография сердца в диагностике гипертрофической кардиомиопатии и стратификации риска внезапной сердечной смерти. Клин. И эксперимент. хир. Журн. им. акад. Б.В. Петровского. 2019;7(3):70–78. [Mershina E.A., Sinitsyn V.E., Larina O.M. Cardiac magnetic resonance in diagnosis of hypertrophic cardiomyopathy and sudden cardiac death risk stratification. Clin. Experiment. Surg. Petrovsky J. 2019;7(3):70–78. (In Russ.)]. DOI: 10.24411/2308-1198-2019-13008.
Баев М.С., Рыжков А.В., Гаврилова Е.А., Труфанов Г.Е. Клиническое применение Т1-картирования миокарда: обзор литературы и первый опыт клинического применения. Сибирский журнал клинической и экспериментальной медицины. 2022;37(1):17–26. [Baev M.S., Ryzhkov A.V., Gavrilova E.A., Trufanov G.E. Clinical application of T1-myocardial mapping: Review of literature and first experience of clinical application. The Siberian Journal of Clinical and Experimental Medicine. 2022;37(1):17–26. (In Russ.)]. DOI: 10.29001/2073-8552-2022-37-1-17-26.
Małek Ł.A., Werys K., Kłopotowski M., S ́piewak M., Miłosz-Wieczorek B., Mazurkiewicz Ł. et al. Native T1-mapping for non-contrast assessment of myocardial fi brosis in patients with hypertrophic cardiomyopathy – comparison with late enhancement quantifi cation. Magn. Reson. Imaging. 2015;33(6):718–724. DOI: 10.1016/j.mri.2015.04.001.
Huang L., Ran L., Zhao P., Tang D., Han R., Ai T. et al. MRI native T1 and T2 mapping of myocardial segments in hypertrophic cardiomyopathy: tissue remodeling manifested prior to structure changes. Br. J. Radiol. 2019;92(1104):20190634. DOI: 10.1259/bjr.20190634.
Baig M., Galazka P., Dakwar O., Syed S.A., Sawlani R., Shahir K. et al. Prevalence of myocardial edema with T2-mapping in hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 2021;77(18 Suppl. 1):1303. DOI: 10.1016/s0735-1097(21)02661-9.
Ridouani F., Damy T., Tacher V., Derbel H., Legou F., Sifaoui I. et al. Myocardial native T2 measurement to diff erentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J. Cardiovasc. Magn. Reson. 2018;20(1):58. DOI: 10.1186/s12968-018-0478-3.
Pan J.A., Kerwin M.J., Salerno M. Native T1 mapping, extracellular volume mapping, and late gadolinium enhancement in cardiac amyloidosis: a meta-analysis. JACC Cardiovasc. Imaging. 2020;13(6):1299–1310. DOI: 10.1016/j.jcmg.2020.03.010.
Banypersad S.M. The evolving role of cardiovascular magnetic reso-nance imaging in the evaluation of systemic amyloidosis. Magn. Reson. Insights. 2019;12:1178623X19843519. DOI: 10.1177/1178623X19843519.
Slivnick J.A., Tong M.S., Nagaraja H.N., Elamin M.B., Wallner A., O’Brien A. et al. Novel cardiovascular magnetic resonance model to distinguish immunoglobulin light chain from transthyretin cardiac amyloidosis. JACC Cardiovasc. Imaging. 2021;14(1):302–304. DOI: 10.1016/j.jcmg.2020.07.030.
Kotecha T., Martinez-Naharro A., Treibel T.A, Francis R., Nordin S., Abdel-Gadir A. et al. Myocardial edema and prognosis in amyloidosis. J. Am. Coll. Cardiol. 2018;71(25):2919–2931. DOI: 10.1016/j.jacc.2018.03.536.
Kampmann C., Linhart A., Baehner F., Palecek T., Wiethoff C.M., Miebach E. et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int. J. Cardiol. 2008;130(3):367–373. DOI: 10.1016/j.ijcard.2008.03.007.
Krä mer J., Niemann M., Stö rk S., Frantz S., Beer M., Ertl G. et al. Relation of burden of myocardial fi brosis to malignant ventricular arrhythmias and outcomes in Fabry disease. Am. J. Cardiol. 2014;114(6):895–900. DOI: 10.1016/j.amjcard.2014.06.019.
Patel V., O’Mahony C., Hughes D., Rahman M.S., Coats C., Murphy E. et al. Clinical and genetic predictors of major cardiac events in patients with Anderson-Fabry disease. Heart. 2015;101(12):961–966. DOI: 10.1136/heartjnl-2014-306782.
Germain D.P., Charrow J., Desnick R.J., Guff on N., Kempf J., Lachmann R.H. et al. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J. Med. Genet. 2015;52(5):353–358. DOI: 10.1136/jmedgenet-2014-102797.
Motwani M., Banypersad S., Woolfson P., Waldek S. Enzyme replacement therapy improves cardiac features and severity of Fabry disease. Mol. Genet. Metab. 2012;107(1–2):197–202. DOI: 10.1016/j.ymgme.2012.05.011.
Beck M., Hughes D., Kampmann C., Larroque S., Mehta A., Pintos-Morell G., et al.; Fabry Outcome Survey Study Group. Long-term eff ectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis. Mol. Genet. Metab. Rep. 2015;3:21–27. DOI: 10.1016/j.ymgmr.2015.02.002.
Moon J.C., Sachdev B., Elkington A.G., McKenna W.J., Mehta A., Pennell D.J. et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specifi c abnormalityof the myocardial interstitium. Eur. Heart J. 2003;24(23):2151–2155. DOI: 10.1016/j.ehj.2003.09.017.
Militaru S., Ginghina C., Popescu B.A., Saftoiu A., Linhart A., Jurcut R. Multimodality imaging in Fabry cardiomyopathy: from early diagnosis to therapeutic targets. Eur. Heart J. Cardiovasc. Imaging. 2018;19(12):1313–1322. DOI: 10.1093/ehjci/jey132.
Nordin S., Kozor R., Bulluck H., Castelletti S., Rosmini S., Abdel-Gadir A. et al. Cardiac fabry disease with late gadolinium enhancement is a chronic infl ammatory cardiomyopathy. J. Am. Coll. Cardiol. 2016;68(15):1707–1708. DOI: 10.1016/j.jacc.2016.07.741.
Messroghli D.R., Moon J.C., Ferreira V.M., Grosse-Wortmann L., He T., Kellman P. et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: a consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J. Cardiovasc. Magn. Reson. 2017;19(1):75. DOI: 10.1186/s12968-017-0389-8.
Sado D.M., Maestrini V., Piechnik S.K., Banypersad S.M., White S.K., Flett A.S. et al. Noncontrast myocardial T1 mapping using cardiovascular magnetic resonance for iron overload. J. Magn. Reson. Imaging. 2015;41(6):1505–1511. DOI: 10.1002/jmri.24727.
Torlasco C., Cassinerio E., Roghi A., Faini A., Capecchi M., Abdel- Gadir A. et al. Role of T1 mapping as a complementary tool to T2* for non-invasive cardiac iron overload assessment. PLoS One. 2018;13(2):e0192890. DOI: 10.1371/journal.pone.0192890.
60 Krittayaphong R., Zhang S., Saiviroonporn P., Viprakasit V., Tanapibunpon P., Komoltri C. et al. Detection of cardiac iron overload with native magnetic resonance T1 and T2 mapping in patients with thalassemia. Int. J. Cardiol. 2017;248:421–426. DOI: 10.1016/j.ijcard.2017.06.100.

Еще

Статья обзорная